CTRI/2021/11/038265招募中3 期
FDG PET-CT based risk adapted Radiotherapy Vs Observation for post chemotherapy residual mass in advanced Seminoma: A Prospective Randomised Controlled Trial(PROSem) - PROSem
Tata Memorial Centre Department of Atomic Energy Clinical Trial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Histological diagnosis of classical seminoma
- •2.Primary site – testis, mediastinum, or retroperitoneum
- •3.Stage IIB-IIIC (AJCC 8th edition)
- •4.Age >18 years
- •5.Karnofsky Performance Status at least 70
- •6.A response assessment FDG PETCT scan done at least twelve weeks after the first-line chemotherapy, showing a persistent measurable residual mass
- •7.Patient willing and reliable for follow-up and QOL.
排除标准
- •1.Histology other than classical seminoma
- •2.Non completion of planned first-line chemotherapy
- •3.Prior history of radiotherapy to the involved region
- •4.Inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist
研究者
相似试验
已完成
不适用
Benefit of modification of radiotherapy treatment plan at mid treatment for head and neck cancer patientsCTRI/2019/03/018049Basavatrakam Indo American Cancer Hospital and Research Institute Hyderabad20
招募中
不适用
PET/CT based radiotherapy treatment planning for cancermalignant tumorJPRN-UMIN000003522Yokohama City University, School of Medicine100
已完成
不适用
Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial SarcoidosisMyocardial sarcoidosisJPRN-UMIN000022996The Department of Cardiology, Nagoya University Graduate School of Medicine50
进行中（未招募）
不适用
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 15.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-005473-22-DKEORTC570
尚未招募
3 期
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research GroupAdvanced stage Hodgkin Lymphoma10025319NL-OMON39829European Organisation for Research in Treatment of Cancer (EORTC)190